Evolus, Inc. (NASDAQ: EOLS) Reports Q4 and Full-Year 2025 Financial Results: Sixth Consecutive Year of Double-Digit Growth, Sustainable Profitability Expected in 2026

Key Highlights

• Total Net Revenue: Q4 2025 net revenue reached \$90.3 million (up 14% YoY); full-year 2025 revenue was \$297.2 million (up 12% YoY).
• Profitability Achieved: GAAP operating income of \$4.2 million in Q4 2025; non-GAAP operating income of \$7.1 million, exceeding guidance. Evolus expects to achieve sustainable profitability beginning in 2026.
• Operating Leverage: Full-year non-GAAP operating expenses of \$209.7 million were within guidance, with a 4% decline in expenses in H2 2025 over H1. Guidance for 2026 sees only 0%–3% expense growth.
• 2026 Guidance: Net revenue expected between \$327 million and \$337 million (10%–13% growth); non-GAAP operating expenses guided to \$210–\$216 million. Adjusted EBITDA margin projected at low- to mid-single digits for 2026, expanding to 13%–15% by 2028.
• Product Portfolio Expansion: U.S. launch of Evolysse™ and upcoming European launch of Estyme® expected to drive growth, with injectable HA gels anticipated to contribute 10%–12% of 2026 revenue.
• Customer Metrics: Over 17,700 cumulative accounts; >3,000 customers have purchased Evolysse™, with U.S. account penetration above 55%. Customer reorder rate remains robust at ~71%.
• Strong Loyalty Program: Evolus Rewards™ membership grew by over 76,000 in Q4, approaching 1.4 million, up 30% year-over-year. Total redemptions reached a record high (over 249,000), with ~70% repeat treatments among existing patients.
• Balance Sheet: Cash and equivalents of \$53.8 million at year-end 2025, up from \$43.5 million at September 30, 2025.
• Long-term Financial Outlook: 2028 net revenue expected at \$450–\$500 million (15%–19% three-year CAGR), with adjusted EBITDA margins of 13%–15%.

Detailed Financial and Strategic Overview

1. Revenue and Profitability

Evolus delivered its sixth consecutive year of double-digit net revenue growth, driven by the continued success of flagship product Jeuveau® and the expansion of its injectable portfolio. Q4 2025 revenue was \$90.3 million, with annual revenue of \$297.2 million. Global toxin (Jeuveau®) revenue for 2025 was \$274.5 million, and injectable HA gels contributed \$22.6 million.

The company reported Q4 2025 GAAP operating income of \$4.2 million (versus a loss of \$2.3 million in Q4 2024) and non-GAAP operating income of \$7.1 million (versus \$6.7 million in Q4 2024). Full-year 2025 GAAP operating loss was \$32.7 million, but non-GAAP operating loss narrowed to \$9.4 million (from a slight profit in 2024), with over \$4 million in non-GAAP operating income generated in H2 2025.

2. Operating Expenses and Leverage

Full-year 2025 non-GAAP operating expenses were \$209.7 million, up from \$185.0 million in 2024 but within guidance (\$208–\$213 million). The company implemented expense reduction measures in Q2 2025, resulting in a 4% sequential drop in H2 expenses. 2026 non-GAAP operating expense guidance is flat to slightly up (\$210–\$216 million, 0%–3% growth), supporting further operating leverage.

3. 2026 and Long-Term Guidance

Evolus projects 2026 net revenue of \$327–\$337 million (10%–13% YoY growth). Adjusted gross profit margin is guided to 65.5%–67.0% (slight compression from 2025, reflecting product mix). Injectable HA gels (Evolysse™ and Estyme®) are expected to drive 10%–12% of 2026 revenue, with the anticipated U.S. launch of Evolysse™ Sculpt in Q4 2026 (no revenue contribution assumed in guidance).

The company expects to achieve a low- to mid-single digit adjusted EBITDA margin in 2026, expanding to 13%–15% by 2028 as market share grows, the portfolio expands, and European launches scale. The three-year CAGR for revenue is expected at 15%–19%, with a more conservative outlook for U.S. market growth.

4. Commercial Execution and Customer Metrics

• Total purchasing accounts increased by over 600 in Q4 alone, with more than 17,700 cumulative customers and U.S. account penetration above 55% for Evolysse™.
• Customer reorder rates remain strong at ~71%, indicating high engagement and retention.
• Evolus Rewards™ consumer loyalty program membership approached 1.4 million, up 30% YoY, with total redemptions at an all-time high and repeat treatment rates of ~70% among existing patients.

5. Cash Flow and Balance Sheet

Cash and equivalents stood at \$53.8 million at December 31, 2025 (from \$86.95 million at end-2024), reflecting ongoing investments in growth. Operating cash flow was negative for the year but positive in Q4, with prudent expense management and improving working capital trends.

Total assets at year-end were \$225.9 million, with total liabilities of \$249.0 million and stockholders’ deficit of \$23.1 million.

6. Tariff and Regulatory Considerations

• Jeuveau® is not currently impacted by tariffs.
• Evolysse™ (imported from France) is subject to a 10% tariff, with potential for an additional 5% pending U.S. administration action. Evolus is evaluating the recovery of previously paid tariffs overturned by the Supreme Court and will continue monitoring policy developments.

7. Change in Profitability Metric

Beginning in 2026, Evolus will transition its primary profitability metric from non-GAAP Operating Income (Loss) to Adjusted EBITDA, aligning with industry peers and enhancing comparability for investors.

Shareholder-Relevant and Potentially Price-Sensitive Items

• Profitability Achieved: Evolus delivered positive operating income in Q4 2025 and expects to maintain profitability (as measured by Adjusted EBITDA) in 2026 and beyond.
• Disciplined Expense Management: Expense actions taken in 2025 are delivering operating leverage, setting the stage for margin expansion and stronger earnings power.
• Product Portfolio and Approvals: Multiple growth catalysts ahead, including the European launch of Estyme®, the anticipated U.S. approval of Evolysse™ Sculpt in late 2026, and growing adoption of the injectable HA gel portfolio.
• Strong Customer Metrics: Continuing growth in accounts, high reorder rates, and loyalty program expansion support durable revenue growth and recurring sales.
• Tariff and Policy Risks: While Jeuveau® is not tariff-impacted, Evolysse™ faces ongoing tariff exposure and regulatory uncertainty, which could impact future profitability.
• Balance Sheet and Cash Flow: Cash reserves are sufficient for current operations, but ongoing investment and negative cash flow for 2025 highlight the need for continued discipline and potential future capital management actions.
• Long-Term Outlook: Management’s 2028 guidance implies significant upside for revenue and margins if execution remains on track, making Evolus a potential growth story in the aesthetics space.

Conclusion

Evolus, Inc. has delivered strong financial results for Q4 and full-year 2025, achieving meaningful profitability milestones, operating leverage, and customer growth. 2026 guidance and the long-term outlook suggest further revenue and margin expansion, supported by new product launches and disciplined expense management. Investors should closely monitor progress on the European Estyme® launch, U.S. approval of Evolysse™ Sculpt, and ongoing tariff developments, as well as Evolus’s ability to convert operating performance into sustained free cash flow and positive shareholder returns.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult their financial advisors before making investment decisions. All forward-looking statements are subject to risks and uncertainties as outlined in the company’s filings with the SEC.

View Evolus, Inc. Historical chart here